IGC Pharma (IGC) CEO acquires 706,409 shares via equity awards
IGC Pharma, Inc. CEO Mukunda Ram acquired a total of 706,409 shares of common stock on April 1, 2026, through the exercise of restricted stock units and stock options. These transactions are described as routine compensation-related vesting and option exercises, not discretionary buying or selling. Following these acquisitions, Ram directly holds 4,649,088 shares, with an additional 910,751 shares held indirectly by his spouse.
FEB 17·Yahoo! Finance Canada▲
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
IGC Pharma announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for patent No. 3,095,729, protecting the proprietary composition of IGC-AD1, their Phase 2 clinical stage program for agitation in Alzheimer's disease. This secures North American composition protection for IGC-AD1, reinforcing its long-term exclusivity as enrollment for the Phase 2 CALMA trial approaches completion. The company emphasized that this intellectual property strengthening enhances the durability and commercial positioning of IGC-AD1, which is a low-dose THC formulation combined with other ingredients.
FEB 17·Stock Titan▲
Low-dose THC Alzheimer’s drug from IGC wins key North America patent
IGC Pharma announced that it has secured North American composition protection for its low-dose THC Alzheimer's drug, IGC-AD1, following a Notice of Allowance from the Canadian Intellectual Property Office. This patent covers the specific formulation as its Phase 2 CALMA trial, targeting agitation in Alzheimer's disease, approaches 70% enrollment completion. The company believes this strengthens the long-term exclusivity and commercial positioning of IGC-AD1.
